References
- Yang JJ , ChengC, DevidasM et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120(20) , 4197–4204 (2012).
- Borowitz MJ , DevidasM, HungerSP et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children‘s Oncology Group study. Blood 111(12) , 5477–5485 (2008).
- Freidlin B , JiangW, SimonR. The cross-validated adaptive signature design. Clin. Cancer Res.16(2) , 691–698 (2010).
- Holleman A , CheokMH, den Boer ML et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med.351(6) , 533–542 (2004).
References
- Crews KR , GaedigkA, DunnenbergerHM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2) , 321–326 (2012).
- Relling MV , GardnerEE, SandbornWJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3) , 387–391 (2011).
- Hicks JK , CrewsKR, HoffmanJM et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin. Pharmacol. Ther. 92(5) , 563–566 (2012).
- Gaedigk A , SimonSD, PearceRE et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2) , 234–242 (2008).
References
- Kim H , KangHJ, KimHJ et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS ONE 7(9) , e45558 (2012).
- Hutchinson RJ , GaynonPS, SatherH et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children‘s Cancer Group Trial 1881. J. Clin. Oncol. 21(9) , 1790–1797 (2003).
- Lange BJ , BostromBC, CherlowJM et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children‘s Cancer Group. Blood 99(3) , 825–833 (2002).
- Broxson EH , DoleM, WongR et al. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr. Blood Cancer 44(3) , 226–231 (2005).
- Marsh S , van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin. Pharmacol. Ther.85(2) , 139–141 (2009).
- Cheok MH , EvansWE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer6(2) , 117–129 (2006).
- Adam de Beaumais T , Jacqz-AigrainE. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol.68(9) , 1233–1242 (2012).
References
- Fernandez CA , SmithC, YangW et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin. Pharmacol. Ther. 92(3) , 360–365 (2012).
- Deeken J . The Affymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther.11(3) , 260–268 (2009).
- Sissung TM , EnglishBC, VenzonD, FiggWD, DeekenJF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics11(1) , 89–103 (2010).